Taking into account these findings and the compelling number of reports highlighting the ability of BET inhibitors to challenge progression of several forms of cancer18–21 and the promising prospect of developing (+)-JQ1 derivatives in the clinic22, we asked whether BET proteins are involved in the transcriptional activation of catabolic genes in cancer cachexia, and whether the BET small inhibitor (+)-JQ1 may have a beneficial effect by preventing muscle wasting. The gene discussed is DNER; the disease is cancer.